CyclerATX is developing targeted protein degradation technology specifically for extracellular drivers of neuropsychiatric and neurodegenerative diseases. This approach aims to create effective protein degraders that can significantly enhance treatment outcomes for patients suffering from these conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Many neuropsychiatric and neurodegenerative diseases are driven by extracellular proteins that are difficult to target with traditional therapies. Current treatments often lack the specificity needed to address these extracellular drivers effectively, leading to limited efficacy and potential side effects.
Solution
CyclerATX is developing a targeted protein degradation (TPD) technology, CYpHER, specifically engineered to address extracellular proteins implicated in central nervous system (CNS) diseases. This approach aims to create highly selective protein degraders capable of eliminating disease-causing extracellular proteins. By focusing on extracellular targets, CyclerATX seeks to overcome the limitations of conventional drugs and develop more effective treatments for neuropsychiatric and neurodegenerative conditions. The CYpHER platform is designed to create protein degraders that can access and degrade proteins that are otherwise inaccessible to traditional intracellular TPD approaches.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel treatments for neuropsychiatric and neurodegenerative diseases.
Features
- CYpHER platform designed for extracellular protein degradation
- Focus on creating degraders for previously undruggable extracellular targets
- Potential for improved efficacy and reduced off-target effects compared to traditional therapies
- Applicability to a range of neuropsychiatric and neurodegenerative diseases